Navigation Links
NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards

NEW YORK, Nov. 9, 2010 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that NeoStem's Chairman and CEO, Dr. Robin L. Smith, M.D., MBA, will be honored tonight at Moves Magazine's 2010 Power Women Awards Dinner & Ceremony beginning at 6:30 pm at the Astor Center, 399 Lafayette Street, New York City.

This event marks the seventh year of the Moves Power Women Awards. The event will be hosted by Kerry Washington, an actor and member of the President's Committee on the Arts and Humanities. According to Moves Magazine, the 2010 Power Women Awards honors "successful and influential women of substance… power women."

Robin Smith commented, "I am honored to be among such fabulous women. As an entrepreneur, philanthropist, and physician, my life is centered around others and my greatest reach will be through my work at NeoStem, where we focus on adult stem cells and search for ways to repair damaged tissues and find treatments and cures for many debilitating diseases and conditions. We also enable healthy adults to have their stem cells stored should they be needed in the future as a Bio-insurance."

About NeoStem, Inc.NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit:

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contactNeoStem, Inc.Robin SmithPhone: +1 (212) 584-4174E-mail: rsmith@neostem.com

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
2. FOX Business Network Airing In-Depth Look at NeoStem
3. NeoStem to Present at Rodman & Renshaws 12th Annual Healthcare Conference
4. NeoStem Provides Second Quarter Update
5. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
6. NeoStem Named Best Stem Cell Company in The New Economys 2010 Biotech Awards
7. NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
8. NeoStem Raises $5 Million in Registered Direct Offering
9. NeoStem Selected to Present at American Society for Apheresis
10. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
11. NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):